I’ve been thinking about the parallels between two seemingly disparate fields that I find myself deeply entrenched in: IVF treatments and startup investing. It was a recent consultation with a patient that really brought this connection to light. This young woman, full of hope but also aware of the challenges ahead, reminded me of a founder I once backed. Both were embarking on journeys filled with uncertainty, where the stakes were high and the outcomes unpredictable.
In both IVF and startups, we are dealing with high-risk, high-reward scenarios. The unpredictable nature of both fields demands a robust framework for handling risk. In the IVF clinic, this means adopting a comprehensive risk assessment framework, especially for patients with underlying health conditions. The GRASP mnemonic — Genetics, Retrieval, Anaesthetics, Stimulation, Pregnancy — has been instrumental in guiding our approach. It ensures we cover all bases, from genetic considerations to potential pregnancy complications.
Similarly, in the startup world, assessing risk involves understanding a market’s potential, the capability of the founding team, and the feasibility of the technology at hand. Much like an IVF patient who might downplay their health conditions, founders often present a rosy picture, omitting the potential pitfalls. As an investor, it’s crucial to dig deeper, just as we do in IVF, to understand the full scope of the situation.
A founder I backed once told me, “The risk is part of the excitement.” This resonates with the sentiment many IVF patients express. The hope of a new beginning, whether it’s a baby or a business, often outweighs the fear of failure. However, this hope should not blind us to the realities of the journey. In both domains, the importance of informed consent cannot be overstated. Just as we ensure our patients understand the risks involved in IVF, founders must grasp the challenges their startups might face.
The increasing number of women with underlying health conditions seeking IVF reflects a broader societal trend — women are starting families later, much like how people pursue entrepreneurial ventures after gaining some life experience. This shift brings with it a need for tailored risk management strategies. In IVF, we collaborate with maternal medicine specialists to create a comprehensive care plan. Similarly, in the startup ecosystem, involving mentors and advisors who can provide a broader perspective is invaluable.
In my experience, the most successful IVF treatments and startups are those that are approached with a blend of optimism and realism. This balance is critical. It’s about acknowledging the risks while still daring to hope for the best outcome. I recall a particular case where a patient, despite her complex medical history, was determined to pursue IVF. Her unwavering resolve reminded me of a founder who weathered multiple pivots, each time emerging with a clearer vision and renewed vigor.
The financial aspect is another common thread. IVF treatments can be prohibitively expensive, much like the capital requirements for scaling a startup. The prohibitive costs often deter many from pursuing these paths. In both scenarios, innovative financing solutions are emerging. Fertility insurance products and outcome-based pricing models are making IVF more accessible. In the startup realm, we’re seeing a rise in alternative funding models that reduce the financial burden on entrepreneurs.
One might think that the regulatory burdens in IVF are unique, but they mirror those in the startup world, especially in sectors requiring regulatory approval. The lengthy timelines and significant investment required to bring a medical product to market are akin to the journey of developing a new IVF treatment or protocol. This is a deterrent for many investors, yet it is here that the greatest innovations often lie.
In both fields, failure is a real possibility. But it’s the lessons learned from these failures that often pave the way for future success. A failed IVF cycle or a startup that didn’t take off are not the end of the road; they are stepping stones. This is a sentiment I explored further in “The IVF Decision That Changed My Approach to Risk-taking in Startups” (https://www.indianangel.in/the-ivf-decision-that-changed-my-approach-to-risk-taking-in-startups/).
Ultimately, the unseen connection between risk in startups and IVF treatments lies in the human element. The hopes, dreams, and perseverance of the individuals involved drive both fields. It’s these stories of resilience, like the one I shared in “How IVF Patients Teach Me About the Importance of Resilience in Startups” (https://www.indianangel.in/how-ivf-patients-teach-me-about-the-importance-of-resilience-in-startups/), that continually inspire me.
As I reflect on these parallels, I’m reminded that while the paths may be fraught with challenges, the potential rewards make the journey worthwhile. Whether it’s helping a couple achieve their dream of parenthood or supporting a founder in bringing an innovative idea to life, the impact we can have is profound. And that, to me, is the true essence of my work in both IVF and angel investing.